1. Home

Latest news

Preserving the Brain: LIRH Foundation joins Fondazione Prada's 'call to action'

EMA has agreed to evaluate the MAA for pridopidine for the treatment of Huntington's disease

Lega Italiana Ricerca Huntington continues to grow: LIRH Umbria is born!

Update from Skyhawk Therapeutics on the Phase 1 clinical trial with SKY-0515.

Today, on Women's Day, the LIRH Friuli Venezia Giulia Association is officially born.

Pridopidine for Huntington's disease now available through an expanded access/compassionate use program

Predicting the Severity of Imminent Huntington Disease

Breakthrough in the study of Huntington's disease: an alteration in the pediatric HD is not present in the adult HD

The phase 2A Pivot-HD clinical study for Huntington disease starts today in Italy

The results of the PROOF-HD study in Huntington's disease are not as expected

Rare Disease Day 2023. Doing well is possible. The example of Huntington's disease.

Clinical trials on Huntington Disease. LIRH Annuale Conference: Rome, December 3, 2022

Huntington's disease trials: update on Vibrant-HD (Novartis) and AMT-130 (uniQure).

LIRH Foundation sheds a light on Florence for Huntington's disease

LIRH Sardegna and LIRH Foundation meet the HD families to talk about research and care

Huntington patients at the forefront of the right to care: the LIRH Sardinia Association was born

Rare Disease Day 2022: The colors of Huntington Disease

First Patients dosing in European Open-Label AMT-130 Gene Therapy trial for Huntington's

Oral drugs, the new frontier in fighting the cause of Huntington's disease

Huntington's signs in the first months of life described in a recent study

Roche announced a phase II study with tominersen. Do we know enough?

Hobbies help get better, according to a study conducted on people with Huntington's disease.

Clinical Update on First Patients in Phase I/II Clinical Trial Gene Therapy for the Treatment of Huntington’s Disease